Voyager Therapeutics, Inc. (VYGR) income statement
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3057% below fair value
$1.53−0.08 (-4.97%)
Close on Nov 20, 2026Market cap $94.28MP/E –Yield –
Voyager Therapeutics, Inc. financial ratios
See a number that looks wrong?